You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrimipramine
Accession NumberDB00726  (APRD00498)
TypeSmall Molecule
GroupsApproved
Description

Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]

Structure
Thumb
Synonyms
10,11-dihydro-N,N,beta-Trimethyl-5H-dibenz[b,F]azepine-5-propanamine
5-(gamma-dimethylamino-beta-Methylpropyl)-10,11-dihydro-5H-dibenzo[b,F]azepine
5-[3-(dimethylamino)-2-Methylpropyl]-10,11-dihydro-5H-dibenz[b,F]azepine
beta-Methylimipramine
RP-7162
Sapilent
Trimeprimina
Trimeprimine
Trimeproprimine
Trimipramina
Trimipramine
Trimipraminum
External Identifiers
  • IF 6120
  • IL 6001
  • RP 7162
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-tripramine Tab 100mg BPtablet100 mgoralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 25mg BPtablet25 mgoralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 50mg BPtablet50 mgoralNovopharm Limited1991-12-312015-10-26Canada
Nu-trimipramine Tab 100mgtablet100 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 12.5mgtablet12.5 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 25mgtablet25 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 50mgtablet50 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Rhotriminetablet100 mgoralSanofi Aventis Canada Inc1988-12-312007-03-29Canada
Rhotriminetablet50 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhotriminetablet25 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhotriminetablet12.5 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhotriminecapsule75 mgoralSanofi Aventis Canada Inc1988-12-312007-03-29Canada
Surmontilcapsule25 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs
Surmontiltablet25 mgoralSanofi Aventis Canada Inc1964-12-312006-07-28Canada
Surmontilcapsule100 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs
Surmontiltablet50 mgoralSanofi Aventis Canada Inc1971-12-312006-07-28Canada
Surmontilcapsule50 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs
Surmontil 100tablet100 mgoralAventis Pharma Inc1964-12-312005-08-01Canada
Surmontil 12.5tablet12.5 mgoralAventis Pharma Inc1968-12-312005-08-01Canada
Surmontil 75capsule75 mgoralAventis Pharma Inc1979-12-312005-08-01Canada
Trimipraminetablet100 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminetablet50 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminetablet25 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminetablet12.5 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminecapsule75 mgoralAa Pharma Inc1994-12-31Not applicableCanada
Trimipramine Tab 100mgtablet100 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Trimipramine Tab 12.5mgtablet12.5 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Trimipramine Tab 25mgtablet25 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Trimipramine Tab 50mgtablet50 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Trimipramine-75 - Cap 75mgcapsule75 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trimipraminecapsule75 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet100 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet50 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet25 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet12.5 mgoralApotex IncNot applicableNot applicableCanada
Trimipramine Maleatecapsule25 mg/1oralCross Medika s.a.2016-04-18Not applicableUs
Trimipramine Maleatecapsule25 mg/1oralActavis Pharma, Inc.2011-11-21Not applicableUs
Trimipramine Maleatecapsule100 mg/1oralCross Medika s.a.2016-04-18Not applicableUs
Trimipramine Maleatecapsule100 mg/1oralActavis Pharma, Inc.2011-10-21Not applicableUs
Trimipramine Maleatecapsule50 mg/1oralCross Medika s.a.2016-04-18Not applicableUs
Trimipramine Maleatecapsule50 mg/1oralActavis Pharma, Inc.2011-11-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HerphonalTemmler
SapilentExtractumPharma
StangylSanofi-Aventis
TrimiduraMylan dura
TrimineurinHexal
TripressMylan
TydamineAspen Pharmacare
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Trimipramine maleate
ThumbNot applicableDBSALT000969
Categories
UNII6S082C9NDT
CAS number739-71-9
WeightAverage: 294.4338
Monoisotopic: 294.209598842
Chemical FormulaC20H26N2
InChI KeyInChIKey=ZSCDBOWYZJWBIY-UHFFFAOYSA-N
InChI
InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}-2-methylpropyl)dimethylamine
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Alkyldiarylamine
  • Azepine
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
PharmacodynamicsTrimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.
Mechanism of actionTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Related Articles
AbsorptionRapid absorption
Volume of distributionNot Available
Protein binding93%-96% (to plasma proteins)
Metabolism

Hepatic

Route of eliminationNot Available
Half life11-18 hrs
ClearanceNot Available
ToxicitySide effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9739
Blood Brain Barrier+0.9861
Caco-2 permeable+0.8059
P-glycoprotein substrateSubstrate0.6559
P-glycoprotein inhibitor IInhibitor0.8838
P-glycoprotein inhibitor IIInhibitor0.8826
Renal organic cation transporterInhibitor0.7098
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6698
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9094
CYP450 3A4 inhibitorNon-inhibitor0.6132
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.8109
CarcinogenicityNon-carcinogens0.9021
BiodegradationNot ready biodegradable0.9886
Rat acute toxicity2.8709 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9065
hERG inhibition (predictor II)Inhibitor0.8271
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral75 mg
Tabletoral100 mg
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral50 mg
Capsuleoral100 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Prices
Unit descriptionCostUnit
Trimipramine maleate powder51.0USD g
Surmontil 100 mg capsule5.92USD capsule
Surmontil 50 mg capsule4.15USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Trimipramine 25 mg capsule1.92USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point45 °CPhysProp
water solubilitySlightly solubleNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP4.67ALOGPS
logP4.76ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.02 m3·mol-1ChemAxon
Polarizability35.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-0a4m-5790000000-53c724efbeeb45818f39View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AA06
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSDownload (75 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Trimipramine can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Acetophenazine.
Acetylsalicylic acidTrimipramine may increase the antiplatelet activities of Acetylsalicylic acid.
AclidiniumAclidinium may increase the anticholinergic activities of Trimipramine.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Trimipramine.
AmisulprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amisulpride.
AmphetamineTrimipramine may increase the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Trimipramine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aripiprazole.
AzelastineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Trimipramine.
BatimastatThe serum concentration of Trimipramine can be increased when it is combined with Batimastat.
BenzquinamideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Benzquinamide.
BexaroteneThe serum concentration of Trimipramine can be decreased when it is combined with Bexarotene.
BortezomibThe metabolism of Trimipramine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Trimipramine can be decreased when it is combined with Bosentan.
Botulinum Toxin Type ATrimipramine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTrimipramine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
BuprenorphineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BupropionThe metabolism of Trimipramine can be decreased when combined with Bupropion.
ButabarbitalThe metabolism of Trimipramine can be increased when combined with Butabarbital.
ButethalThe metabolism of Trimipramine can be increased when combined with Butethal.
CarphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Carphenazine.
CathinoneTrimipramine may increase the stimulatory activities of Cathinone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorpromazine.
ChlorpropamideTrimipramine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorprothixene.
CimetidineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.
Cimetropium BromideTrimipramine may increase the anticholinergic activities of Cimetropium Bromide.
CinacalcetThe serum concentration of Trimipramine can be increased when it is combined with Cinacalcet.
CitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.
ClozapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clozapine.
ConivaptanThe serum concentration of Trimipramine can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.
DasatinibThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.
DesmopressinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Trimipramine.
DicoumarolTrimipramine may increase the anticoagulant activities of Dicoumarol.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Trimipramine.
DofetilideTrimipramine may increase the QTc-prolonging activities of Dofetilide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DuloxetineDuloxetine may increase the serotonergic activities of Trimipramine.
EluxadolineTrimipramine may increase the activities of Eluxadoline.
EscitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.
EthanolTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FencamfamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fencamfamine.
FluconazoleThe metabolism of Trimipramine can be decreased when combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimipramine.
FlupentixolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trimipramine.
FosaprepitantThe serum concentration of Trimipramine can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Trimipramine can be increased when it is combined with Fusidic Acid.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Trimipramine is combined with Glucagon recombinant.
GoserelinTrimipramine may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Trimipramine.
HaloperidolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Haloperidol.
HeptabarbitalThe metabolism of Trimipramine can be increased when combined with Heptabarbital.
HexobarbitalThe metabolism of Trimipramine can be increased when combined with Hexobarbital.
HydrocodoneTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
IcosapentTrimipramine may increase the antiplatelet activities of Icosapent.
IdelalisibThe serum concentration of Trimipramine can be increased when it is combined with Idelalisib.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Trimipramine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Trimipramine.
IsoflurophateThe serum concentration of Trimipramine can be increased when it is combined with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Trimipramine.
IvacaftorThe serum concentration of Trimipramine can be increased when it is combined with Ivacaftor.
LeuprolideTrimipramine may increase the QTc-prolonging activities of Leuprolide.
LinezolidLinezolid may increase the serotonergic activities of Trimipramine.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Trimipramine.
LithiumLithium may increase the neurotoxic activities of Trimipramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trimipramine.
LoxapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Loxapine.
LuliconazoleThe serum concentration of Trimipramine can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
MesoridazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mesoridazine.
MethohexitalThe metabolism of Trimipramine can be increased when combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methotrimeprazine.
Methylene blueTrimipramine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimipramine.
MetyrosineTrimipramine may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Trimipramine.
MidodrineTrimipramine may increase the activities of Midodrine.
MifepristoneThe serum concentration of Trimipramine can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
MirabegronThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mirabegron.
MitotaneThe serum concentration of Trimipramine can be decreased when it is combined with Mitotane.
MolindoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Morphine.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Trimipramine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
NelfinavirThe metabolism of Trimipramine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Trimipramine can be increased when it is combined with Netupitant.
NicorandilTrimipramine may increase the hypotensive activities of Nicorandil.
OlanzapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ondansetron.
OrciprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Orciprenaline.
OrphenadrineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PalbociclibThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Paliperidone.
PanobinostatThe serum concentration of Trimipramine can be increased when it is combined with Panobinostat.
ParaldehydeTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.
Peginterferon alfa-2bThe serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Trimipramine can be increased when combined with Pentobarbital.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
PerphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perphenazine.
PhenelzinePhenelzine may increase the serotonergic activities of Trimipramine.
PhenytoinThe metabolism of Trimipramine can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Piperacetazine.
Potassium ChlorideTrimipramine may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleTrimipramine may increase the sedative activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Trimipramine.
PrimidoneThe metabolism of Trimipramine can be increased when combined with Primidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Trimipramine.
PromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Quetiapine.
QuinidineTrimipramine may increase the QTc-prolonging activities of Quinidine.
RamosetronTrimipramine may increase the activities of Ramosetron.
RemoxiprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Risperidone.
RitonavirThe metabolism of Trimipramine can be decreased when combined with Ritonavir.
RopiniroleTrimipramine may increase the sedative activities of Ropinirole.
RotigotineTrimipramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trimipramine.
SecobarbitalThe metabolism of Trimipramine can be increased when combined with Secobarbital.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Trimipramine.
SertindoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Trimipramine.
SiltuximabThe serum concentration of Trimipramine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Trimipramine can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
St. John's WortThe metabolism of Trimipramine can be increased when combined with St. John's Wort.
StiripentolThe serum concentration of Trimipramine can be increased when it is combined with Stiripentol.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Trimipramine.
SuvorexantTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Trimipramine can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Trimipramine.
TerbinafineThe metabolism of Trimipramine can be decreased when combined with Terbinafine.
ThalidomideTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThioridazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thiothixene.
TiclopidineThe metabolism of Trimipramine can be decreased when combined with Ticlopidine.
TiotropiumTrimipramine may increase the anticholinergic activities of Tiotropium.
TocilizumabThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.
TopiramateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Topiramate.
TramadolTrimipramine may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Trimipramine.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Trimipramine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Triflupromazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Trimipramine.
Valproic AcidThe serum concentration of Trimipramine can be increased when it is combined with Valproic Acid.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Trimipramine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziprasidone.
ZolpidemTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Diamond M, Kelly JP, Connor TJ: Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4. [PubMed:16388933 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
desensitize the target
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Eikmeier G, Muszynski K, Berger M, Gastpar M: High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial. Pharmacopsychiatry. 1990 Sep;23(5):212-4. [PubMed:1979173 ]
Kind
Protein
Organism
Rat
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
Htr2c
Uniprot ID:
P08909
Molecular Weight:
51916.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 21, 2016 09:38